{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:54:03Z","timestamp":1778622843342,"version":"3.51.4"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11934-020-01024-8","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T02:02:16Z","timestamp":1610157736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Conservative Therapy for Peyronie\u2019s Disease: a Contemporary Review of the Literature"],"prefix":"10.1007","volume":"22","author":[{"given":"Ayad","family":"Yousif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Natale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J. G.","family":"Hellstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"1024_CR1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","volume":"157","author":"CJ Devine Jr","year":"1997","unstructured":"Devine CJ Jr, et al. Proposal: trauma as the cause of the Peyronie\u2019s lesion. J Urol. 1997;157:285\u201390.","journal-title":"J Urol"},{"issue":"2","key":"1024_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.sxmr.2019.06.004","volume":"8","author":"KL Sharma","year":"2020","unstructured":"Sharma KL, Alom M, Trost L. The etiology of Peyronie\u2019s disease: pathogenesis and genetic contributions. Sex Med Rev. 2020;8(2):314\u201323. https:\/\/doi.org\/10.1016\/j.sxmr.2019.06.004.","journal-title":"Sex Med Rev"},{"key":"1024_CR3","doi-asserted-by":"publisher","first-page":"282503","DOI":"10.1155\/2011\/282503","volume":"2011","author":"DB Dibenedetti","year":"2011","unstructured":"Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie\u2019s disease: prevalence and treatment patterns in the United States. Ther Adv Urol. 2011;2011:282503\u20139. https:\/\/doi.org\/10.1155\/2011\/282503.","journal-title":"Ther Adv Urol"},{"issue":"7","key":"1024_CR4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","volume":"88","author":"U Schwarzer","year":"2001","unstructured":"Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie\u2019s disease: results of a large survey. BJU Int. 2001;88(7):727\u201330.","journal-title":"BJU Int"},{"issue":"Suppl 5","key":"1024_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bju.14605","volume":"122","author":"E Chung","year":"2018","unstructured":"Chung E, Gillman M, Rushton D, Love C, Katz D. Prevalence of penile curvature: a population-based cross-sectional study in metropolitan and rural cities in Australia. BJU Int. 2018;122(Suppl 5):42\u20139.","journal-title":"BJU Int"},{"issue":"2","key":"1024_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajur.2015.04.019","volume":"2","author":"AA Hussein","year":"2015","unstructured":"Hussein AA, Alwaal A, Lue TF. All about Peyronie\u2019s disease. Asian J Urol. 2015;2(2):70\u20138. https:\/\/doi.org\/10.1016\/j.ajur.2015.04.019.","journal-title":"Asian J Urol"},{"issue":"3","key":"1024_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"\u2022 Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie\u2019s disease: AUA guideline. J Urol. 2015;194(3):745\u201353. https:\/\/doi.org\/10.1016\/j.juro.2015.05.098. A systematic review of the literature was performed to create guidelines pertinent to the diagnosis and treatment of Peyronie\u2019s disease. AUA recommendations are based on consensus of scientific evidence.","journal-title":"J Urol"},{"key":"1024_CR8","unstructured":"\u2022 EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam. 2020. ISBN 978\u201394\u201392671-07-3. A systematic review of the literature was performed to create guidelines pertinent to the diagnosis and treatment of Peyronie\u2019s disease. EAU recommendations are based on consensus of scientific evidence."},{"issue":"6","key":"1024_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","volume":"13","author":"E Chung","year":"2016","unstructured":"Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-based management guidelines on Peyronie\u2019s disease. J Sex Med. 2016;13(6):905\u201323. https:\/\/doi.org\/10.1016\/j.jsxm.2016.04.062.","journal-title":"J Sex Med"},{"issue":"2","key":"1024_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.sxmr.2018.09.007","volume":"7","author":"SC Brimley","year":"2019","unstructured":"Brimley SC, Yafi FA, Greenberg J, Hellstrom WJG, Tue Nguyen HM, Hatzichristodoulou G. Review of management options for active-phase Peyronie\u2019s disease. Sex Med Rev. 2019;7(2):329\u201337. https:\/\/doi.org\/10.1016\/j.sxmr.2018.09.007.","journal-title":"Sex Med Rev"},{"key":"1024_CR11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0022-5347(17)66108-1","volume":"81","author":"CJ Zarafonetis","year":"1959","unstructured":"Zarafonetis CJ, Horrax TM. Treatment of Peyronie\u2019s disease with potassium para-aminobenzoate (potaba). J Urol. 1959;81:770\u20132.","journal-title":"J Urol"},{"key":"1024_CR12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","volume":"47","author":"W Weidner","year":"2005","unstructured":"Weidner W, Hauck EW, Schnitker J, et al. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie\u2019s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530\u20135.","journal-title":"Eur Urol"},{"issue":"1","key":"1024_CR13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5534\/wjmh.2016.34.1.40","volume":"34","author":"TY Park","year":"2016","unstructured":"Park TY, Jeong HG, Park JJ, Chae JY, Kim JW, Oh MM, et al. The efficacy of medical treatment of Peyronie\u2019s disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor. World J Mens Health. 2016;34(1):40\u20136.","journal-title":"World J Mens Health"},{"issue":"2","key":"1024_CR14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000488976","volume":"12","author":"L Al Attar","year":"2018","unstructured":"Al Attar L, Kilgore W. Rare incidence of acute liver injury with potassium para-aminobenzoate introduction. Case Rep Gastroenterol. 2018;12(2):230\u20133 Published 2018 May 31.","journal-title":"Case Rep Gastroenterol"},{"issue":"1458","key":"1024_CR15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.56.1458.650","volume":"56","author":"HM Evans","year":"1922","unstructured":"Evans HM, Bishop KS. On the existence of a hitherto unrecognized dietary factor essential for reproduction. Science. 1922;56(1458):650\u20131.","journal-title":"Science"},{"issue":"5","key":"1024_CR16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.ijir.3900880","volume":"14","author":"SC Sikka","year":"2002","unstructured":"Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie\u2019s disease. Int J Impot Res. 2002;14(5):353\u201360.","journal-title":"Int J Impot Res"},{"key":"1024_CR17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00007611-194802000-00017","volume":"41","author":"WW Scott","year":"1948","unstructured":"Scott WW, Scardino PL. A new concept in the treatment of Peyronie\u2019s disease. South Med J. 1948;41:173\u20137.","journal-title":"South Med J"},{"issue":"4 Pt 1","key":"1024_CR18","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"MR Safarinejad","year":"2007","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4 Pt 1):1398\u2013403 discussion 1403.","journal-title":"J Urol"},{"issue":"3","key":"1024_CR19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1590\/S1677-55382004000300004","volume":"30","author":"JA Claro","year":"2004","unstructured":"Claro JA, Passerotti CC, Figueiredo Neto AC, Nardozza A Jr, Ortiz V, Srougi M. An alternative non-invasive treatment for Peyronie\u2019s disease. Int Braz J Urol. 2004;30(3):199\u2013204.","journal-title":"Int Braz J Urol"},{"issue":"1","key":"1024_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","volume":"1","author":"G Paulis","year":"2013","unstructured":"Paulis G, Brancato T, D\u2019Ascenzo R, de Giorgio G, Nupieri P, Orsolini G, et al. Efficacy of vitamin E in the conservative treatment of Peyronie\u2019s disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120\u20138.","journal-title":"Andrology."},{"key":"1024_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/RRU.S141748","volume":"9","author":"G Paulis","year":"2017","unstructured":"Paulis G, Paulis A, Romano G, Barletta D, Fabiani A. Rationale of combination therapy with antioxidants in medical management of Peyronie\u2019s disease: results of clinical application. Res Rep Urol. 2017;9:129\u201339. Published 2017 Jul 20. https:\/\/doi.org\/10.2147\/RRU.S141748.","journal-title":"Res Rep Urol"},{"issue":"6","key":"1024_CR22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jsxm.2019.03.404","volume":"16","author":"H Porst","year":"2019","unstructured":"Porst H, Burri A, European Society for Sexual Medicine (ESSM) Educational Committee. Current strategies in the management of Peyronie\u2019s disease (PD)-results of a survey of 401 sexual medicine experts across Europe [published correction appears in J Sex Med. 2019 Sep;16(9):1486]. J Sex Med. 2019;16(6):901\u20138.","journal-title":"J Sex Med"},{"issue":"6","key":"1024_CR23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/j.1743-6109.2010.01790.x","volume":"7","author":"AW Shindel","year":"2010","unstructured":"Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, et al. Pentoxifylline attenuates transforming growth factor-\u03b21-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med. 2010;7(6):2077\u201385.","journal-title":"J Sex Med"},{"issue":"2","key":"1024_CR24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","volume":"106","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie\u2019s disease [retracted in: Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. BJU Int. 2015 Mar;115(3):E10]. BJU Int. 2010;106(2):240\u20138.","journal-title":"BJU Int"},{"issue":"4","key":"1024_CR25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.esxm.2019.07.003","volume":"7","author":"A Ibrahim","year":"2019","unstructured":"Ibrahim A, Gazzard L, Alharbi M, Rompr\u00e9-Brodeur A, Aube M, Carrier S. Evaluation of oral pentoxifylline, colchicine, and penile traction for the management of Peyronie\u2019s disease. Sex Med. 2019;7(4):459\u201363.","journal-title":"Sex Med"},{"key":"1024_CR26","first-page":"1","volume":"8","author":"G Paulis","year":"2015","unstructured":"Paulis G, Barletta D, Turchi P, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie\u2019s disease: a case-control study. Res Rep Urol. 2015;8:1\u201310 Published 2015 Dec 31.","journal-title":"Res Rep Urol"},{"issue":"4","key":"1024_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.acuro.2018.08.005","volume":"43","author":"L Gallo","year":"2019","unstructured":"Gallo L, Sarnacchiaro P. Ten-year experience with multimodal treatment for acute phase Peyronie\u2019s disease: a real life clinical report. Diez a\u00f1os de experiencia con el tratamiento multimodal de la fase aguda de la enfermedad de Peyronie: reporte m\u00e9dico de la vida real. Actas Urol Esp. 2019;43(4):182\u20139. https:\/\/doi.org\/10.1016\/j.acuro.2018.08.005.","journal-title":"Actas Urol Esp"},{"issue":"4","key":"1024_CR28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"9","author":"EG Valente","year":"2003","unstructured":"Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229\u201344.","journal-title":"Nitric Oxide"},{"issue":"5","key":"1024_CR29","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/j.1743-6109.2011.02217.x","volume":"8","author":"E Chung","year":"2011","unstructured":"Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8(5):1472\u20137.","journal-title":"J Sex Med"},{"issue":"3","key":"1024_CR30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","volume":"183","author":"U Ozturk","year":"2014","unstructured":"Ozturk U, Yesil S, Goktug HN, et al. Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction. Ir J Med Sci. 2014;183(3):449\u201353.","journal-title":"Ir J Med Sci"},{"issue":"2","key":"1024_CR31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2018.10.014","volume":"75","author":"MM Ilg","year":"2019","unstructured":"Ilg MM, Mateus M, Stebbeds WJ, Milenkovic U, Christopher N, Muneer A, et al. Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie\u2019s disease models. Eur Urol. 2019;75(2):329\u201340.","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"1024_CR32","doi-asserted-by":"publisher","first-page":"S269","DOI":"10.21037\/tau.2019.08.06","volume":"9","author":"MR Farrell","year":"2020","unstructured":"Farrell MR, Ziegelmann MJ, Levine LA. Minimally invasive therapies for Peyronie\u2019s disease: the current state of the art. Transl Androl Urol. 2020;9(Suppl 2):S269\u201383. https:\/\/doi.org\/10.21037\/tau.2019.08.06.","journal-title":"Transl Androl Urol"},{"issue":"10","key":"1024_CR33","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jsxm.2018.08.012","volume":"15","author":"A Cocci","year":"2018","unstructured":"Cocci A, Cito G, Urz\u00ec D, Minervini A, di Maida F, Sessa F, et al. Sildenafil 25 mg ODT + collagenase Clostridium hystoliticum vs collagenase Clostridium hystoliticum alone for the management of Peyronie\u2019s disease: a matched-pair comparison analysis. J Sex Med. 2018;15(10):1472\u20137. https:\/\/doi.org\/10.1016\/j.jsxm.2018.08.012.","journal-title":"J Sex Med"},{"issue":"11","key":"1024_CR34","doi-asserted-by":"crossref","first-page":"775","DOI":"10.4111\/kju.2015.56.11.775","volume":"56","author":"E Chung","year":"2015","unstructured":"Chung E. Peyronie\u2019s disease and low intensity shock wave therapy: clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men. Korean J Urol. 2015;56(11):775\u201380.","journal-title":"Korean J Urol"},{"issue":"6","key":"1024_CR35","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/S0022-5347(05)64173-0","volume":"168","author":"DJ Martin","year":"2002","unstructured":"Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168(6):2483\u20135.","journal-title":"J Urol"},{"issue":"Suppl 3","key":"1024_CR36","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijir.3900558","volume":"12","author":"MS Anderson","year":"2000","unstructured":"Anderson MS, Shankey TV, Lubrano T, Mulhall JP. Inhibition of Peyronie\u2019s plaque fibroblast proliferation by biologic agents. Int J Impot Res. 2000;12(Suppl 3):S25\u201331.","journal-title":"Int J Impot Res"},{"issue":"4","key":"1024_CR37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","volume":"51","author":"J Rehman","year":"1998","unstructured":"Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie\u2019s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620\u20136.","journal-title":"Urology."},{"issue":"2","key":"1024_CR38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"WP Fitch 3rd","year":"2007","unstructured":"Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie\u2019s disease-a placebo-controlled pilot study. J Sex Med. 2007;4(2):477\u201384.","journal-title":"J Sex Med"},{"issue":"4","key":"1024_CR39","first-page":"407","volume":"25","author":"XW Qiu","year":"2005","unstructured":"Qiu XW, Wang JH, Fang XW, Gong ZY, Li ZQ, Yi ZH. Di Yi Jun Yi Da Xue Xue Bao. 2005;25(4):407\u201310.","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"issue":"2","key":"1024_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ijir.2015.22","volume":"28","author":"J Twidwell","year":"2016","unstructured":"Twidwell J, Levine L. Topical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study [published correction appears in Int J Impot Res. 2020 Jun 2]. Int J Impot Res. 2016;28(2):41\u20135. https:\/\/doi.org\/10.1038\/ijir.2015.22.","journal-title":"Int J Impot Res"},{"issue":"4","key":"1024_CR41","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","volume":"171","author":"SM Di Stasi","year":"2004","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease. J Urol. 2004;171(4):1605\u20138.","journal-title":"J Urol"},{"issue":"3","key":"1024_CR42","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","volume":"177","author":"JM Greenfield","year":"2007","unstructured":"Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie\u2019s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972\u20135.","journal-title":"J Urol"},{"issue":"9","key":"1024_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11934-016-0622-2","volume":"17","author":"LA Aliperti","year":"2016","unstructured":"Aliperti LA, Mehta A. Peyronie\u2019s disease: intralesional therapy and surgical intervention. Curr Urol Rep. 2016;17(9):60. https:\/\/doi.org\/10.1007\/s11934-016-0622-2.","journal-title":"Curr Urol Rep"},{"issue":"1","key":"1024_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jsxm.2019.09.022","volume":"17","author":"S Sukumar","year":"2020","unstructured":"Sukumar S, Pijush DB, Brandes S. Impact of the advent of collagenase Clostridium histolyticum on the surgical management of Peyronie\u2019s disease: a population-based analysis. J Sex Med. 2020;17(1):111\u20136. https:\/\/doi.org\/10.1016\/j.jsxm.2019.09.022.","journal-title":"J Sex Med"},{"key":"1024_CR45","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0022-5347(17)35291-6","volume":"151","author":"LA Levine","year":"1994","unstructured":"Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie\u2019s disease. J Urol. 1994;151:1522\u20134.","journal-title":"J Urol"},{"key":"1024_CR46","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0022-5347(01)64224-1","volume":"158","author":"LA Levine","year":"1997","unstructured":"Levine LA. Treatment of Peyronie\u2019s disease with intralesional verapamil injection. J Urol. 1997;158:1395\u20139.","journal-title":"J Urol"},{"key":"1024_CR47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","volume":"168","author":"LA Levine","year":"2002","unstructured":"Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie\u2019s disease. J Urol. 2002;168:621\u20135; discussion 625\u2013626.","journal-title":"J Urol"},{"key":"1024_CR48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","volume":"41","author":"M Shirazi","year":"2009","unstructured":"Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41:467\u201371.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"1024_CR49","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/andr.12368","volume":"5","author":"V Favilla","year":"2017","unstructured":"Favilla V, Russo GI, Zucchi A, Siracusa G, Privitera S, Cimino S, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie\u2019s disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017;5(4):771\u20135.","journal-title":"Andrology."},{"issue":"6","key":"1024_CR50","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.eururo.2018.07.005","volume":"74","author":"GI Russo","year":"2018","unstructured":"\u2022\u2022 Russo GI, Milenkovic U, Hellstrom W, Levine LA, Ralph D, Albersen M. Clinical efficacy of injection and mechanical therapy for Peyronie\u2019s disease: a systematic review of the literature. Eur Urol. 2018;74(6):767\u201381. https:\/\/doi.org\/10.1016\/j.eururo.2018.07.005. This systematic review includes evidence synthesized from available literature. The study reported that there is sufficient evidence to suggest that CCH and IFN\u03b1-2b injection therapy have a clinically significant effect on improving penile curvature and conserving penile length. There was no sufficient evidence to support the use of other injection and mechanical treatments for PD.","journal-title":"Eur Urol"},{"key":"1024_CR51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365599109024539","volume":"25","author":"MR Duncan","year":"1991","unstructured":"Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie\u2019s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25:89\u201394.","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"1024_CR52","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJG Hellstrom","year":"2006","unstructured":"Hellstrom WJG, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon \u03b1-2b for minimally invasive treatment for Peyronie\u2019s disease. J Urol. 2006;176(1):394\u20138.","journal-title":"J Urol"},{"issue":"6","key":"1024_CR53","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2013.05.022","volume":"190","author":"LW Trost","year":"2013","unstructured":"Trost LW, et al. Outcomes of Intralesional Interferon-\u03b12B for the Treatment of Peyronie Disease. J Urol. 2013;190(6):2194\u20139.","journal-title":"J Urol"},{"issue":"6","key":"1024_CR54","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.juro.2015.06.096","volume":"194","author":"CA Stewart","year":"2015","unstructured":"Stewart CA, et al. Intralesional injection of interferon-\u03b12b improves penile curvature in men with Peyronie\u2019s disease independent of plaque location. J Urol. 2015;194(6):1704\u20137.","journal-title":"J Urol"},{"issue":"20","key":"1024_CR55","doi-asserted-by":"publisher","first-page":"30009","DOI":"10.1016\/j.sxmr.2020.01.005","volume":"S2050\u20130521","author":"C Natale","year":"2020","unstructured":"Natale C, McLellan DM, Yousif A, Hellstrom WJG. Review of intralesional collagenase Clostridium histolyticum injection therapy and related combination therapies in the treatment of Peyronie\u2019s disease (an update) [published online ahead of print, 2020 Mar 18]. Sex Med Rev. 2020;S2050\u20130521(20):30009\u20133. https:\/\/doi.org\/10.1016\/j.sxmr.2020.01.005.","journal-title":"Sex Med Rev"},{"key":"1024_CR56","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo-controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol"},{"key":"1024_CR57","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J Sex Med. 2015;12:248\u201358.","journal-title":"J Sex Med"},{"issue":"6","key":"1024_CR58","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/JU.0000000000000743","volume":"203","author":"I Goldstein","year":"2020","unstructured":"\u2022 Goldstein I, et al. Long-term safety and curvature deformity characterization in patients previously treated with collagenase Clostridium histolyticum for Peyronie\u2019s disease. J Urol. 2020;203(6):1191\u20137. This phase-4 study included men previously enrolled in either the IMPRESS trials or the open-label studies of CCH. While 280 patients were included in the study, only 204 completed the study. Of these, 180 showed additional penile curvature improvement at 5-year follow-up. Patients also showed improvement in PDQ bother domain mean score. This study reports sustained long-term improvement in penile curvature in patients treated with CCH therapy at 5-year follow-up without further CCH treatment.","journal-title":"J Urol"},{"key":"1024_CR59","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","volume":"14","author":"HMT Nguyen","year":"2017","unstructured":"Nguyen HMT, Anaissie J, DeLay KJ, et al. Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease. J Sex Med. 2017;14:1220\u20135.","journal-title":"J Sex Med"},{"issue":"4","key":"1024_CR60","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/JU.0000000000000032","volume":"201","author":"WJG Hellstrom","year":"2019","unstructured":"\u2022\u2022 Hellstrom WJG, et al. Intralesional collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie\u2019s disease: results of a multi-institutional analysis. J Urol. 2019;201(4):777\u201382. First large, multi-institutional study which occurred at institutions where the IMPRESS trial was instituted for the routine treatment of PD. This study reported no difference in response to CCH therapy in the acute vs. stable phases of PD. This study also illustrated that number of cycles was predictive of curvature improvement.","journal-title":"J Urol"},{"key":"1024_CR61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.urology.2019.01.055","volume":"129","author":"M Alom","year":"2019","unstructured":"Alom M, et al. Safety and efficacy of collagenase Clostridium histolyticum in Peyronie\u2019s disease men with ventral curvatures. Urology. 2019;129:119\u201325.","journal-title":"Urology"},{"issue":"1","key":"1024_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5534\/wjmh.190026","volume":"38","author":"A Cocci","year":"2020","unstructured":"Cocci A, Di Maida F, Russo GI, et al. How atypical penile curvature influence clinical outcomes in patients with Peyronie\u2019s disease receiving collagenase Clostridium histolyticum therapy? World J Mens Health. 2020;38(1):78\u201384. https:\/\/doi.org\/10.5534\/wjmh.190026.","journal-title":"World J Mens Health"},{"issue":"2","key":"1024_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00345-019-02850-3","volume":"38","author":"TA Masterson","year":"2020","unstructured":"Masterson TA, Rezk A, Ramasamy R. Characteristics predictive of response to collagenase Clostridium histolyticum for Peyronie\u2019s disease: a review of the literature. World J Urol. 2020;38(2):279\u201385. https:\/\/doi.org\/10.1007\/s00345-019-02850-3.","journal-title":"World J Urol"},{"key":"1024_CR64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","volume":"10","author":"MK Gelbard","year":"1982","unstructured":"Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie\u2019s disease experimental studies. Urol Res. 1982;10:135\u201340.","journal-title":"Urol Res"},{"key":"1024_CR65","doi-asserted-by":"crossref","unstructured":"\u2022 Abdel Raheem A, Capece M, Kalejaiye O, et al. Safety and effectiveness of collagenase Clostridium histolyticum (CCH) (Xiapex\u00ae) in the treatment of Peyronie\u2019s disease using a new modified shortened protocol. BJU Int. 2017;120(5):717\u201323. In this prospective study of 53 subjects at a single center, patients underwent a shortened, nonrandomized protocol of 3 CCH injections at 4-week intervals in combination with manual modeling, stretching, and vacuum device on a daily basis. Reported results were similar to those of the IMPRESS trials, indicating that a shortened protocol may be appropriate in some patients.","DOI":"10.1111\/bju.13932"},{"issue":"6","key":"1024_CR66","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/bju.14784","volume":"124","author":"E Fern\u00e1ndez-Pascual","year":"2019","unstructured":"Fern\u00e1ndez-Pascual E, Gonz\u00e1lez-Garc\u00eda FJ, Angulo J, Cerezo E, Quintana LM, Turo J, et al. Optimizing collagenase Clostridium histolyticum therapy for Peyronie\u2019s disease using a novel approach with percutaneous needle tunnelling. BJU Int. 2019;124(6):1055\u201362. https:\/\/doi.org\/10.1111\/bju.14784.","journal-title":"BJU Int"},{"key":"1024_CR67","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-G\u00f3mez B, Garc\u00eda-Rojo E, Alonso-Isa M, et al. Treatment of Peyronie\u2019s disease with combination of Clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study [published online ahead of print, 2020 May 4]. Int J Impot Res. 2020. https:\/\/doi.org\/10.1038\/s41443-020-0292-y.","DOI":"10.1038\/s41443-020-0292-y"},{"key":"1024_CR68","doi-asserted-by":"crossref","unstructured":"Hughes W, Natale C, Hellstrom WJG. The management of penile fracture: a review of the literature with special consideration for patients undergoing collagenase Clostridium histolytica injection therapy. Curr Urol Rep. 2020; (In Press).","DOI":"10.1007\/s11934-020-01025-7"},{"issue":"119","key":"1024_CR69","doi-asserted-by":"crossref","first-page":"pe6","DOI":"10.1126\/stke.2002.119.pe6","volume":"2002","author":"FJ Alenghat","year":"2002","unstructured":"Alenghat FJ, Ingber DE. Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Sci STKE. 2002;2002(119):pe6.","journal-title":"Sci STKE"},{"issue":"3","key":"1024_CR70","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JU.0000000000000245","volume":"202","author":"M Ziegelmann","year":"2019","unstructured":"Ziegelmann M, Savage J, Toussi A, et al. Outcomes of a novel penile traction device in men with Peyronie\u2019s disease: a randomized, single-blind, controlled trial. J Urol. 2019;202(3):599\u2013610.","journal-title":"J Urol"},{"issue":"6","key":"1024_CR71","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","volume":"16","author":"M Alom","year":"2019","unstructured":"Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie\u2019s disease. J Sex Med. 2019;16(6):891\u2013900. https:\/\/doi.org\/10.1016\/j.jsxm.2019.03.007.","journal-title":"J Sex Med"},{"key":"1024_CR72","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","volume":"104","author":"MJ Ziegelmann","year":"2017","unstructured":"\u2022 Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW. Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease. Urology. 2017;104:102\u20139. https:\/\/doi.org\/10.1016\/j.urology.2017.01.054. In this randomized-controlled trial of 110 patients with PD and curvature of 30\u00b0 or greater, patients were assigned to either 30 or 90\u00a0min of traction therapy per day with the RestoreX device. The study reported significant improvement in penile curvature and length in those treated with the traction device compared to the control group. Time for traction therapy treatment in this study was significantly shorter than is typically required.","journal-title":"Urology"},{"issue":"3","key":"1024_CR73","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.juro.2015.03.092","volume":"194","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Pinsky MR, Stewart C, Sangkum P, Ates E, Trost LW, et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie\u2019s disease. J Urol. 2015;194(3):754\u20138. https:\/\/doi.org\/10.1016\/j.juro.2015.03.092.","journal-title":"J Urol"},{"key":"1024_CR74","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urology.2018.07.039","volume":"122","author":"NM Haney","year":"2018","unstructured":"\u2022 Haney NM, Kohn TP, Nichols PE, Hellstrom WJ. The effect of adjunct mechanical traction on penile length in men undergoing primary treatment for Peyronie\u2019s disease: a systematic review and meta-analysis. Urology. 2018;122:110\u20135. https:\/\/doi.org\/10.1016\/j.urology.2018.07.039. This systematic review evaluated 4 studies, and 348 total patients, which included penile traction therapy as an adjunct treatment for PD. On meta-analysis, there was a significantly greater stretched penile length in men treated with traction therapy after their primary intervention compared to those not treated with penile traction. This improvement was not significantly different in the surgical vs. injection therapy subgroups.","journal-title":"Urology"},{"issue":"9","key":"1024_CR75","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jsxm.2019.06.010","volume":"16","author":"K Wymer","year":"2019","unstructured":"\u2022 Wymer K, Kohler T, Trost L. Comparative cost-effectiveness of surgery, collagenase Clostridium histolyticum, and penile traction therapy in men with Peyronie\u2019s disease in an era of effective clinical treatment. J Sex Med. 2019;16(9):1421\u201332. This cost analysis determined that RestoreX traction therapy was the most cost-effective treatment compared to surgery and CCH therapy.","journal-title":"J Sex Med"},{"key":"1024_CR76","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1464-410X.2010.09365.x","volume":"106","author":"AA Raheem","year":"2010","unstructured":"Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie\u2019s disease. BJU Int. 2010;106:1178\u201380.","journal-title":"BJU Int"},{"issue":"3","key":"1024_CR77","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.sxmr.2018.11.002","volume":"7","author":"MG Cowper","year":"2019","unstructured":"Cowper MG, Burkett CB, Le TV, Scherzer N, Hellstrom WJG. Penile stretching as a treatment for Peyronie\u2019s disease: a review. Sex Med Rev. 2019;7(3):508\u201315. https:\/\/doi.org\/10.1016\/j.sxmr.2018.11.002.","journal-title":"Sex Med Rev"},{"key":"1024_CR78","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0094-0143(21)01597-4","volume":"15","author":"JE Lingeman","year":"1988","unstructured":"Lingeman JE, McAteer JA, Kempson SA, Evan AP. Bioeffects of extracorporeal shock wave lithotripsy: strategy for research and treatment. Urol Clin North Am. 1988;15:507\u201314.","journal-title":"Urol Clin North Am"},{"key":"1024_CR79","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"A Palmieri","year":"2009","unstructured":"Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie\u2019s disease. Eur Urol. 2009;56:363\u201370.","journal-title":"Eur Urol"},{"key":"1024_CR80","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","volume":"106","author":"S Chitale","year":"2010","unstructured":"Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie\u2019s disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352\u20136.","journal-title":"BJU Int"},{"key":"1024_CR81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","volume":"35","author":"A Palmieri","year":"2012","unstructured":"Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35:190\u20135.","journal-title":"Int J Androl"},{"key":"1024_CR82","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1111\/jsm.12275","volume":"10","author":"G Hatzichristodoulou","year":"2013","unstructured":"Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie\u2019s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10:2815\u201321.","journal-title":"J Sex Med"},{"issue":"3","key":"1024_CR83","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5534\/wjmh.180100","volume":"37","author":"M Di Mauro","year":"2019","unstructured":"\u2022 Di Mauro M, Russo GI, Della Camera PA, et al. Extracorporeal shock wave therapy in Peyronie\u2019s disease: clinical efficacy and safety from a single-arm observational study. World J Mens Health. 2019;37(3):339\u201346. https:\/\/doi.org\/10.5534\/wjmh.180100. In this single-arm, multi-institutional study, 325 consecutive patients were treated with ESWT for PD. The authors reported significant reductions in median plaque size and penile curvature, as well as increased median erect penile length and IIEF and improved PDQ subdomains.","journal-title":"World J Mens Health"},{"key":"1024_CR84","unstructured":"Sexual Medicine Society of North America. Position statement: ED restorative (Regenerative) therapies (shock waves, autologous platelet rich plasma, and stem cells). 27 March, 2018. PDF: https:\/\/www.smsna.org\/V1\/images\/SMSNA_Position_Statement_RE_Restorative_Therapies.pdf. Accessed 25 Sept 2020."},{"issue":"4","key":"1024_CR85","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.adro.2018.07.009","volume":"3","author":"G Pietsch","year":"2018","unstructured":"Pietsch G, Anzeneder T, Bruckbauer H, et al. Superficial radiation therapy in Peyronie\u2019s disease: an effective and well-tolerated therapy. Adv Radiat Oncol. 2018;3(4):548\u201351. Published 2018 Aug 7. https:\/\/doi.org\/10.1016\/j.adro.2018.07.009.","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"1024_CR86","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41585-018-0117-7","volume":"16","author":"P Tsambarlis","year":"2019","unstructured":"Tsambarlis P, Levine LA. Nonsurgical management of Peyronie\u2019s disease. Nat Rev Urol. 2019;16(3):172\u201386. https:\/\/doi.org\/10.1038\/s41585-018-0117-7.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"1024_CR87","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.adro.2016.05.003","volume":"1","author":"J Mahmood","year":"2016","unstructured":"Mahmood J, Shamah AA, Creed TM, et al. Radiation-induced erectile dysfunction: recent advances and future directions. Adv Radiat Oncol. 2016;1(3):161\u20139 Published 2016 Jun 3.","journal-title":"Adv Radiat Oncol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-020-01024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-020-01024-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-020-01024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T02:08:13Z","timestamp":1670724493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-020-01024-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s11934-020-01024-8","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"23 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Wayne Hellstrom is on a speakers\u2019 bureau for Endo Pharmaceuticals and was a principal investigator on the IMPRESS and \u201cReal World\u201d trials. No other author reports any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"6"}}